Published in Health Business Week, November 18th, 2005
The patent, when issued, will provide patent protection for Xyotax in Japan until 2018. In addition to this licensed patent property in Japan, CTI has licensed issued patents in the United States and allowed coverage in Europe that encompass Xyotax.
Currently, CTI plans to submit a new drug application (NDA) and seek approval for Xyotax as first-line monotherapy for women with advanced non-small...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week